Question · asked by 1 review
EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy): Adverse effects
- Population
- People with squamous cell carcinoma of the oral cavity or oropharynx
- Intervention
- EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy)
- Comparison
- Standard therapy alone (radiotherapy or chemoradiotherapy)
- Outcome
- Adverse effects
EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard… led to higher adverse effects compared with standard therapy alone (radiotherapy or chemoradiotherapy); GRADE not reported.
What each review found
Current versions onlyNo studies found 0 · 0%GRADE not reported 10 · 100%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy) Adverse effects · People with squamous cell carcinoma of the oral cavity or oropharynx · 24 to 70 months, Mucositis (all grades) Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy (2015) · Cochrane All outcomes | Mucositis all grades: not estimable due to high heterogeneity (P=0.0009; I2=86%) between subgroups (cetuximab; nimotuzumab) and within cetuximab (I2=93%); 1417 participants, 3 studies. Table 3, row 1.6 (Ang 2014;… | 3 studies · 1417 participants | GRADE not reported |
EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy) Adverse effects · People with squamous cell carcinoma of the oral cavity or oropharynx · 24 to 70 months, Skin toxicity/acneiform rash (cetuximab, all grades) EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard… led to higher adverse effects compared with standard therapy alone (radiotherapy or chemoradiotherapy); GRADE not reported. Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy (2015) · Cochrane All outcomes | RR 6.56 [5.35, 8.03] | 2 studies · 1311 participants | GRADE not reported |
EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy) Adverse effects · People with squamous cell carcinoma of the oral cavity or oropharynx · 24 to 70 months, Xerostomia (grades >=3) EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard… showed no clear difference in adverse effects compared with standard therapy alone (radiotherapy or chemoradiotherapy); GRADE not reported. Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy (2015) · Cochrane All outcomes | RR 1.36 [0.80, 2.31] | 2 studies · 1311 participants | GRADE not reported |
EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy) Adverse effects · People with squamous cell carcinoma of the oral cavity or oropharynx · 24 to 70 months, Skin toxicity/acneiform rash (nimotuzumab, grades >=3) EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard… showed no clear difference in adverse effects compared with standard therapy alone (radiotherapy or chemoradiotherapy); GRADE not reported. Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy (2015) · Cochrane All outcomes | RR 0.20 [0.01, 4.05] | 1 study · 92 participants | GRADE not reported |
EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy) Adverse effects · People with squamous cell carcinoma of the oral cavity or oropharynx · 24 to 70 months, Skin toxicity/acneiform rash (nimotuzumab, all grades) EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard… showed no clear difference in adverse effects compared with standard therapy alone (radiotherapy or chemoradiotherapy); GRADE not reported. Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy (2015) · Cochrane All outcomes | RR 1.06 [0.85, 1.31] | 1 study · 92 participants | GRADE not reported |
EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy) Adverse effects · People with squamous cell carcinoma of the oral cavity or oropharynx · 24 to 70 months, Dysphagia (all grades) EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard… showed no clear difference in adverse effects compared with standard therapy alone (radiotherapy or chemoradiotherapy); GRADE not reported. Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy (2015) · Cochrane All outcomes | RR 0.97 [0.92, 1.03] | 3 studies · 1403 participants | GRADE not reported |
EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy) Adverse effects · People with squamous cell carcinoma of the oral cavity or oropharynx · 24 to 70 months, Skin toxicity/acneiform rash (cetuximab, grades >=3) EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard… led to higher adverse effects compared with standard therapy alone (radiotherapy or chemoradiotherapy); GRADE not reported. Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy (2015) · Cochrane All outcomes | RR 17.72 [8.33, 37.73] | 3 studies · 1403 participants | GRADE not reported |
EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy) Adverse effects · People with squamous cell carcinoma of the oral cavity or oropharynx · 24 to 70 months, Dysphagia (grades >=3) EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard… showed no clear difference in adverse effects compared with standard therapy alone (radiotherapy or chemoradiotherapy); GRADE not reported. Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy (2015) · Cochrane All outcomes | RR 0.93 [0.83, 1.04] | 3 studies · 1403 participants | GRADE not reported |
EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy) Adverse effects · People with squamous cell carcinoma of the oral cavity or oropharynx · 24 to 70 months, Mucositis (grades >=3) EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard… showed no clear difference in adverse effects compared with standard therapy alone (radiotherapy or chemoradiotherapy); GRADE not reported. Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy (2015) · Cochrane All outcomes | RR 1.20 [0.96, 1.51] | 4 studies · 1495 participants | GRADE not reported |
EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy) Adverse effects · People with squamous cell carcinoma of the oral cavity or oropharynx · 24 to 70 months, Xerostomia (all grades) EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard… showed no clear difference in adverse effects compared with standard therapy alone (radiotherapy or chemoradiotherapy); GRADE not reported. Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy (2015) · Cochrane All outcomes | RR 0.97 [0.91, 1.04] | 3 studies · 1417 participants | GRADE not reported |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes | 2015-02 | Not listed | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.